Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.

Identifieur interne : 000A11 ( Main/Exploration ); précédent : 000A10; suivant : 000A12

Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.

Auteurs : Chuan Shen [République populaire de Chine] ; Chenghong Peng [République populaire de Chine] ; Baiyong Shen [République populaire de Chine] ; Zhecheng Zhu [République populaire de Chine] ; Ning Xu [République populaire de Chine] ; Tao Li [République populaire de Chine] ; Junjie Xie [République populaire de Chine]

Source :

RBID : pubmed:27577068

Descripteurs français

English descriptors

Abstract

Immunosuppressive agents used postoperatively after liver transplantation (LT) for hepatocellular carcinoma (HCC) favor recurrence and metastasis. Therefore, new effective immunosuppressants are needed. This retrospective study assessed combined sirolimus and metformin on survival of HCC patients after LT. In 2001-2013, 133 HCC patients with LT were divided into four groups: sirolimus and metformin combination (Sir+Met), sirolimus monotherapy (Sir), other immunosuppressants in diabetes mellitus (DM) patients without metformin (No Sir with DM), and other immunosuppressants in patients without DM (No Sir without DM). Kaplan-Meier and Log-rank tests were used to assess survival. Cell proliferation and tumor xenograft assays were performed to disclose the mechanisms underlying the sirolimus and metformin effects. The Sir+Met group showed significantly prolonged survival compared to the other groups. The most significant cytotoxicity was seen in the Sir+Met group, with significantly decreased levels of phosphorylated PI3K, AKT, AMPK, mTOR, 4EBP1 and S6K, compared with the other groups. In agreement, Sir+Met had the highest suppressive effect on tumor growth among all groups (P<0.01). In summary, Sir+Met treatment significantly prolonged survival, likely by suppressing cell proliferation. Therefore, this combination could represent a potential routine-regimen for patients post LT.

DOI: 10.18632/oncotarget.11591
PubMed: 27577068
PubMed Central: PMC5308754


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.</title>
<author>
<name sortKey="Shen, Chuan" sort="Shen, Chuan" uniqKey="Shen C" first="Chuan" last="Shen">Chuan Shen</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Peng, Chenghong" sort="Peng, Chenghong" uniqKey="Peng C" first="Chenghong" last="Peng">Chenghong Peng</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Shen, Baiyong" sort="Shen, Baiyong" uniqKey="Shen B" first="Baiyong" last="Shen">Baiyong Shen</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zhu, Zhecheng" sort="Zhu, Zhecheng" uniqKey="Zhu Z" first="Zhecheng" last="Zhu">Zhecheng Zhu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Xu, Ning" sort="Xu, Ning" uniqKey="Xu N" first="Ning" last="Xu">Ning Xu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Li, Tao" sort="Li, Tao" uniqKey="Li T" first="Tao" last="Li">Tao Li</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Xie, Junjie" sort="Xie, Junjie" uniqKey="Xie J" first="Junjie" last="Xie">Junjie Xie</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27577068</idno>
<idno type="pmid">27577068</idno>
<idno type="doi">10.18632/oncotarget.11591</idno>
<idno type="pmc">PMC5308754</idno>
<idno type="wicri:Area/Main/Corpus">000977</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000977</idno>
<idno type="wicri:Area/Main/Curation">000977</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000977</idno>
<idno type="wicri:Area/Main/Exploration">000977</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.</title>
<author>
<name sortKey="Shen, Chuan" sort="Shen, Chuan" uniqKey="Shen C" first="Chuan" last="Shen">Chuan Shen</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Peng, Chenghong" sort="Peng, Chenghong" uniqKey="Peng C" first="Chenghong" last="Peng">Chenghong Peng</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Shen, Baiyong" sort="Shen, Baiyong" uniqKey="Shen B" first="Baiyong" last="Shen">Baiyong Shen</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zhu, Zhecheng" sort="Zhu, Zhecheng" uniqKey="Zhu Z" first="Zhecheng" last="Zhu">Zhecheng Zhu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Xu, Ning" sort="Xu, Ning" uniqKey="Xu N" first="Ning" last="Xu">Ning Xu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Li, Tao" sort="Li, Tao" uniqKey="Li T" first="Tao" last="Li">Tao Li</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Xie, Junjie" sort="Xie, Junjie" uniqKey="Xie J" first="Junjie" last="Xie">Junjie Xie</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Oncotarget</title>
<idno type="eISSN">1949-2553</idno>
<imprint>
<date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult (MeSH)</term>
<term>Animals (MeSH)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Carcinoma, Hepatocellular (complications)</term>
<term>Carcinoma, Hepatocellular (drug therapy)</term>
<term>Cell Line, Tumor (MeSH)</term>
<term>Cell Proliferation (MeSH)</term>
<term>Cell Survival (MeSH)</term>
<term>Drug Synergism (MeSH)</term>
<term>Female (MeSH)</term>
<term>Hep G2 Cells (MeSH)</term>
<term>Hepatitis B (drug therapy)</term>
<term>Hepatitis B virus (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Liver Cirrhosis (complications)</term>
<term>Liver Cirrhosis (drug therapy)</term>
<term>Liver Cirrhosis (virology)</term>
<term>Liver Neoplasms (complications)</term>
<term>Liver Neoplasms (drug therapy)</term>
<term>Liver Transplantation (MeSH)</term>
<term>Male (MeSH)</term>
<term>Metformin (administration & dosage)</term>
<term>Mice (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Neoplasm Metastasis (MeSH)</term>
<term>Neoplasm Recurrence, Local (MeSH)</term>
<term>Neoplasm Transplantation (MeSH)</term>
<term>Phosphorylation (MeSH)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Carcinome hépatocellulaire (complications)</term>
<term>Carcinome hépatocellulaire (traitement médicamenteux)</term>
<term>Cellules HepG2 (MeSH)</term>
<term>Cirrhose du foie (complications)</term>
<term>Cirrhose du foie (traitement médicamenteux)</term>
<term>Cirrhose du foie (virologie)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hépatite B (traitement médicamenteux)</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Lignée cellulaire tumorale (MeSH)</term>
<term>Metformine (administration et posologie)</term>
<term>Mâle (MeSH)</term>
<term>Métastase tumorale (MeSH)</term>
<term>Phosphorylation (MeSH)</term>
<term>Prolifération cellulaire (MeSH)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Récidive tumorale locale (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Souris (MeSH)</term>
<term>Survie cellulaire (MeSH)</term>
<term>Synergie des médicaments (MeSH)</term>
<term>Transplantation hépatique (MeSH)</term>
<term>Transplantation tumorale (MeSH)</term>
<term>Tumeurs du foie (complications)</term>
<term>Tumeurs du foie (traitement médicamenteux)</term>
<term>Virus de l'hépatite B (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Metformin</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Immunosuppressive Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Metformine</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Carcinoma, Hepatocellular</term>
<term>Liver Cirrhosis</term>
<term>Liver Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Carcinoma, Hepatocellular</term>
<term>Hepatitis B</term>
<term>Liver Cirrhosis</term>
<term>Liver Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en">
<term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Carcinome hépatocellulaire</term>
<term>Cirrhose du foie</term>
<term>Hépatite B</term>
<term>Tumeurs du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Carcinome hépatocellulaire</term>
<term>Cirrhose du foie</term>
<term>Immunosuppresseurs</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Tumeurs du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Cirrhose du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Liver Cirrhosis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Cell Proliferation</term>
<term>Cell Survival</term>
<term>Drug Synergism</term>
<term>Female</term>
<term>Hep G2 Cells</term>
<term>Hepatitis B virus</term>
<term>Humans</term>
<term>Liver Transplantation</term>
<term>Male</term>
<term>Mice</term>
<term>Middle Aged</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Recurrence, Local</term>
<term>Neoplasm Transplantation</term>
<term>Phosphorylation</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Cellules HepG2</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Phosphorylation</term>
<term>Prolifération cellulaire</term>
<term>Récidive tumorale locale</term>
<term>Résultat thérapeutique</term>
<term>Souris</term>
<term>Survie cellulaire</term>
<term>Synergie des médicaments</term>
<term>Transplantation hépatique</term>
<term>Transplantation tumorale</term>
<term>Virus de l'hépatite B</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Immunosuppressive agents used postoperatively after liver transplantation (LT) for hepatocellular carcinoma (HCC) favor recurrence and metastasis. Therefore, new effective immunosuppressants are needed. This retrospective study assessed combined sirolimus and metformin on survival of HCC patients after LT. In 2001-2013, 133 HCC patients with LT were divided into four groups: sirolimus and metformin combination (Sir+Met), sirolimus monotherapy (Sir), other immunosuppressants in diabetes mellitus (DM) patients without metformin (No Sir with DM), and other immunosuppressants in patients without DM (No Sir without DM). Kaplan-Meier and Log-rank tests were used to assess survival. Cell proliferation and tumor xenograft assays were performed to disclose the mechanisms underlying the sirolimus and metformin effects. The Sir+Met group showed significantly prolonged survival compared to the other groups. The most significant cytotoxicity was seen in the Sir+Met group, with significantly decreased levels of phosphorylated PI3K, AKT, AMPK, mTOR, 4EBP1 and S6K, compared with the other groups. In agreement, Sir+Met had the highest suppressive effect on tumor growth among all groups (P<0.01). In summary, Sir+Met treatment significantly prolonged survival, likely by suppressing cell proliferation. Therefore, this combination could represent a potential routine-regimen for patients post LT.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">27577068</PMID>
<DateCompleted>
<Year>2018</Year>
<Month>03</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1949-2553</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>7</Volume>
<Issue>38</Issue>
<PubDate>
<Year>2016</Year>
<Month>Sep</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>Oncotarget</Title>
<ISOAbbreviation>Oncotarget</ISOAbbreviation>
</Journal>
<ArticleTitle>Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.</ArticleTitle>
<Pagination>
<MedlinePgn>62647-62656</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.11591</ELocationID>
<Abstract>
<AbstractText>Immunosuppressive agents used postoperatively after liver transplantation (LT) for hepatocellular carcinoma (HCC) favor recurrence and metastasis. Therefore, new effective immunosuppressants are needed. This retrospective study assessed combined sirolimus and metformin on survival of HCC patients after LT. In 2001-2013, 133 HCC patients with LT were divided into four groups: sirolimus and metformin combination (Sir+Met), sirolimus monotherapy (Sir), other immunosuppressants in diabetes mellitus (DM) patients without metformin (No Sir with DM), and other immunosuppressants in patients without DM (No Sir without DM). Kaplan-Meier and Log-rank tests were used to assess survival. Cell proliferation and tumor xenograft assays were performed to disclose the mechanisms underlying the sirolimus and metformin effects. The Sir+Met group showed significantly prolonged survival compared to the other groups. The most significant cytotoxicity was seen in the Sir+Met group, with significantly decreased levels of phosphorylated PI3K, AKT, AMPK, mTOR, 4EBP1 and S6K, compared with the other groups. In agreement, Sir+Met had the highest suppressive effect on tumor growth among all groups (P<0.01). In summary, Sir+Met treatment significantly prolonged survival, likely by suppressing cell proliferation. Therefore, this combination could represent a potential routine-regimen for patients post LT.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Chuan</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Peng</LastName>
<ForeName>Chenghong</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Baiyong</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Zhecheng</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Ning</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Tao</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Junjie</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Oncotarget</MedlineTA>
<NlmUniqueID>101532965</NlmUniqueID>
<ISSNLinking>1949-2553</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9100L32L2N</RegistryNumber>
<NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">HCC</Keyword>
<Keyword MajorTopicYN="N">liver transplantation</Keyword>
<Keyword MajorTopicYN="N">mTOR</Keyword>
<Keyword MajorTopicYN="N">metformin</Keyword>
<Keyword MajorTopicYN="N">rapamycin</Keyword>
</KeywordList>
<CoiStatement>The authors declare that they have no conflicts of interest to this study.</CoiStatement>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>11</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2016</Year>
<Month>08</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>9</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2018</Year>
<Month>3</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>9</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27577068</ArticleId>
<ArticleId IdType="pii">11591</ArticleId>
<ArticleId IdType="doi">10.18632/oncotarget.11591</ArticleId>
<ArticleId IdType="pmc">PMC5308754</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Int J Cancer. 2015 Mar 1;136(5):E359-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25220842</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Toxicol Appl Pharmacol. 2013 Sep 1;271(2):229-38</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23707609</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2013 Oct 1;19(19):5372-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23942093</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Med Oncol. 2010 Jun;27(2):255-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19301157</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2015 Jun 01;10(6):e0127967</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26030161</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transplantation. 2007 Feb 27;83(4):425-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17318075</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hepatobiliary Surg Nutr. 2014 Aug;3(4):199-206</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25202697</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18929564</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 2014 Jul 2;312(1):57-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25058218</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Cancer. 2012 May 04;12:166</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22559167</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transplantation. 2016 Jan;100(1):116-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26555945</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Hepatol. 2015 Jun 8;7(10):1355-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26052381</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2016 May;27(5):856-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26884590</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2011 Mar 4;144(5):757-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21376236</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Diabetes Rev. 2013 Sep;9(5):382-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23845075</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2016 Mar 1;7(9):9718-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26756219</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Med. 2013 Dec;2(6):862-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24403259</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Prev Res (Phila). 2012 Mar;5(3):355-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22086681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Pharmacol. 2008 Aug;8(4):393-412</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18721898</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncol Rep. 2013 Nov;30(5):2449-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24008375</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2010 Mar 1;116(5):1315-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20101735</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transpl Int. 2014 Oct;27(10):1039-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24943720</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Manag Care. 2014 Aug 01;20(8):e320-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25295795</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2002 Nov 15;169(10 ):5441-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12421919</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Treat Options Cardiovasc Med. 2014 Dec;16(12):351</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25293340</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2012 Apr 13;149(2):274-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22500797</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pancreas. 2013 Jul;42(5):781-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23462329</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12271141</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Tumour Biol. 2014 Jun;35(6):5101-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24504677</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Gastroenterol. 2013 Jun;108(6):881-91; quiz 892</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23381014</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Dev. 2003 Aug 1;17(15):1829-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12869586</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transplantation. 2005 Apr 15;79(7):855-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15818333</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer. 2012 Nov 20;11:85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23167739</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drugs. 2003;63(18):1879-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12930161</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Transl Med. 2014 Jun;2(6):57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25333032</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2013 May 08;8(5):e63969</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23667692</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):993-1003</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25915713</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Elife. 2014 May 13;3:e02242</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24843020</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Hepatol. 2008 Jul;49(1):52-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18490075</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20126-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21041639</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Amino Acids. 2010 Jan;38(1):223-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19145465</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Fertil Steril. 2012 Apr;97(4):997-1003</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22306710</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocrinology. 2007 Jul;148(7):3246-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17379645</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Hepatol. 2012 Apr;56(4):908-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22424438</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anticancer Drugs. 2014 Nov;25(10):1182-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25035963</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>République populaire de Chine</li>
</country>
</list>
<tree>
<country name="République populaire de Chine">
<noRegion>
<name sortKey="Shen, Chuan" sort="Shen, Chuan" uniqKey="Shen C" first="Chuan" last="Shen">Chuan Shen</name>
</noRegion>
<name sortKey="Li, Tao" sort="Li, Tao" uniqKey="Li T" first="Tao" last="Li">Tao Li</name>
<name sortKey="Peng, Chenghong" sort="Peng, Chenghong" uniqKey="Peng C" first="Chenghong" last="Peng">Chenghong Peng</name>
<name sortKey="Shen, Baiyong" sort="Shen, Baiyong" uniqKey="Shen B" first="Baiyong" last="Shen">Baiyong Shen</name>
<name sortKey="Xie, Junjie" sort="Xie, Junjie" uniqKey="Xie J" first="Junjie" last="Xie">Junjie Xie</name>
<name sortKey="Xu, Ning" sort="Xu, Ning" uniqKey="Xu N" first="Ning" last="Xu">Ning Xu</name>
<name sortKey="Zhu, Zhecheng" sort="Zhu, Zhecheng" uniqKey="Zhu Z" first="Zhecheng" last="Zhu">Zhecheng Zhu</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A11 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A11 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27577068
   |texte=   Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27577068" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020